Canada's healthcare system is under scrutiny as premiers are urged to prioritize improving access to new, life-saving drugs as delays persist. Ahead of the summer premiers’ meeting, Ontario’s Premier Doug Ford highlighted that Canadians face nearly two-year waits for breakthrough medicines, significantly longer than other developed nations, and called for urgent action to match the timely access to treatments available elsewhere.
The Canadian Organization for Rare Disorders pre-budget submission urged the federal government to finalize funding for the National Strategy for Drugs for Rare Diseases and to ensure that Bill C-64, the national pharmacare legislation, prioritizes improved access to medicines for rare diseases. The recommendations include expanding the strategy to cover all provinces and territories and addressing broader issues related to rare disorders.
The federal government's pharmacare plan, as outlined in Bill C-64, is facing criticism, with critics arguing it prioritizes political interests over practical considerations, with calls for its withdrawal or substantial revision.
According to an opinion piece published in iPolitics, the bill's ambitious timeline for implementation and unclear impact on private drug insurance have raised concerns, particularly as Minister of Health Mark Holland's assurances conflict with the legislation's references to a "universal single-payer" system, which may undermine existing private insurance options.
Adding to the complexity, the federal government's plan to penalize provinces for allowing user fees for medically necessary care has raised concerns among private insurers and virtual health companies. They fear it could limit access to popular workplace benefits. Federal Health Minister Mark Holland has promised to clarify how the Canada Health Act applies to virtual and non-physician care following a commitment from his predecessor, Jean-Yves Duclos, to address the rising fees charged by private clinics and virtual care providers.
Meanwhile, public servants continue to grapple with insurance claim issues with MSH International's insurance administration over a year after the Public Service Healthcare Plan update. The Ottawa Citizen reports ongoing struggles with claim reimbursements, communication lapses, and delays.
On a more positive note, Manitoba has implemented the Manitoba Biosimilars Initiative, transitioning the provincial drug plan from covering biologic drugs to biosimilar versions. This move, applauded by Biosimilars Canada, aims to increase patient access to high-quality, cost-effective treatments. Manitoba becomes the tenth Canadian province to adopt such an initiative, following the example set by British Columbia, which reported savings of up to $732 million over five years of implementation.
The ongoing debates and initiatives underscore the delicate balance between improving access to care, managing costs, and navigating the complexities of a multi-faceted healthcare system.
Be updated on the latest stories with Delphic Research today!
